1 / 6
文档名称:

【医学课件】ease研究课件.ppt

格式:ppt   大小:776KB   页数:6页
下载后只包含 1 个 PPT 格式的文档,没有任何的图纸或源代码,查看文件列表

如果您已付费下载过本站文档,您可以点这里二次下载

文档介绍:Ezetimibe Add-on to Statin Therapy for Effectiveness Trial
Presented at
American College of Cardiology
Scientific Sessidl in the coronary heart disease (CHD) or CHD risk equivalent group, 147 mg/dl in the multiple risk factors group, and 167 mg/dl in the <2 risk factors group.

The ezetimibe arm had a larger reduction in triglycerides and a larger increase in high-density lipoprotein (HDL) levels.
Ezetimibe
Placebo
mg/dl
Increase in
High-Density Lipoprotein (HDL)
p<0.001
Ezetimibe
Placebo
Reduction in LDL
p<0.001
Presented at ACC Scientific Sessions 2004
EASE Trial
In the overall study population, a larger percent change from baseline in LDL levels occurred in the ezetimibe arm versus placebo.

The follow-up LDL level in the ezetimibe arm was 95 mg/dl.

A larger percentage of patients in the ezetimibe arm reached target LDL goals.

Results were similar across the different statin brands and by the prespecified subgroups of age group, gender, and diabetes status.
Ezetimibe
Placebo
Reached Target
LDL Goals
p<0.001
mg/dl
Ezetimibe
Placebo
Reduction in LDL
p<0.001
Presented at ACC Scientific Sessions 2004
EASE Trial
Reached Target LDL Goals
p<0.001
mg/dl
Similar results were observed in the CHD/CHD risk equivalent subgroup, the multiple risk factor subgroup, and the <2 CHD risk factor subgroup.
There were no increases in the frequency of alanine aminotransfe

分享好友

预览全文

【医学课件】ease研究课件.ppt

上传人:AIOPIO 8/6/2022 文件大小:776 KB

下载得到文件列表

【医学课件】ease研究课件.ppt

相关文档